Lack of Association between rs2067474 Polymorphism in Histamine Receptor H2 Gene and Breast Cancer in Chinese Han Population
Table 4
Correlations of clinicopathological parameters and HRH2 rs2067474 polymorphism in patients with breast cancer.
rs2067474
GG
GA
AA
Age (years)
46.4 ± 9.2
47.1 ± 8.8
45.6 ± 12.8
0.878a
BMI (kg/m2)
≥25
33 (70.2%)
12 (25.5%)
2 (4.3%)
0.206b
<25
125 (81.2%)
26 (16.9%)
3 (1.9%)
Menopausal state
Premenopausal
102 (81.0%)
21 (16.7%)
3 (2.4%)
0.558b
Postmenopausal
56 (74.7%)
17 (22.7%)
2 (2.7%)
Tumor size (cm)
2.0
37 (84.1%)
5 (11.4%)
2 (4.5%)
0.203b
>2.0
121 (77.1%)
33 (21.0%)
3 (1.9%)
Histology
DIC
137 (77.8%)
36 (20.5%)
3 (1.7%)
0.116b
LIC
8 (88.9%)
1 (11.1%)
0 (0.0%)
Others
13 (81.3%)
1 (6.3%)
2 (12.5%)
Clinical stages
I or II
124 (78.5%)
30 (19.0%)
4 (2.5%)
1.000b
III or IV
34 (79.1%)
8 (18.6%)
1 (2.3%)
Lymph node metastasis
Node-negative
89 (76.7%)
23 (19.8%)
4 (3.4%)
0.606b
Node-positive
69 (81.2%)
15 (17.6%)
1 (1.2%)
Hormone receptor status
Negative
45 (80.4%)
7 (12.5%)
4 (7.1%)
0.016b
Positive
113 (77.9%)
31 (21.4%)
1 (0.7%)
HER2 status
0-1
81 (82.7%)
16 (16.3%)
1 (1.0%)
0.267b
2-3
77 (74.8%)
22 (21.4%)
4 (3.9%)
p53 status
Negative
41 (78.8%)
9 (17.3%)
2 (3.8%)
0.311b
Positive
62 (77.5%)
18 (22.5%)
0 (0.0%)
Undetermined
55 (79.7%)
11 (15.9%)
3 (4.3%)
OR: odd ratio, CI: confidence interval, BMI: body mass index, DIC: ductal invasive carcinoma, LIC: lobular invasive carcinoma, HER2: human epidermal growth factor receptor, and p53: tumor protein 53. a values were calculated by analysis of variance (ANOVA). b values were calculated from two-sided chi-square tests or Fisher’s exact tests.
